+433,968.7%
NVDA vs GSK
+151.0%
+433,817.7%
-89.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | +0.5% | -2.5% | -2.2% |
| 7D | -12.7% | +1.1% | -13.9% | -13.3% |
| 30D | -26.4% | +6.3% | -32.8% | -28.7% |
| 3M | -27.6% | +1.8% | -29.5% | -28.9% |
| 6M | -27.7% | +1.7% | -29.4% | -29.5% |
| YTD | -12.5% | +6.5% | -19.0% | -17.3% |
| 1Y | -12.6% | +9.5% | -22.1% | -18.7% |
| 3Y | +235.9% | +65.3% | +170.6% | +141.6% |
| 5Y | +438.2% | +43.7% | +394.5% | +306.4% |
| 10Y | +7,445.8% | +104.1% | +7,341.7% | +4,566.9% |
| All | +433,968.7% | +151.0% | +433,817.7% | +215,250.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling